These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9523086)

  • 1. The interaction of liposomes with the complement system.
    Szebeni J
    Crit Rev Ther Drug Carrier Syst; 1998; 15(1):57-88. PubMed ID: 9523086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production.
    Moghimi SM; Hamad I; Andresen TL; Jørgensen K; Szebeni J
    FASEB J; 2006 Dec; 20(14):2591-3. PubMed ID: 17065229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids.
    Bradley AJ; Devine DV; Ansell SM; Janzen J; Brooks DE
    Arch Biochem Biophys; 1998 Sep; 357(2):185-94. PubMed ID: 9735159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents.
    Szebeni J
    Crit Rev Ther Drug Carrier Syst; 2001; 18(6):567-606. PubMed ID: 11789676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement in asthma: sensitivity to activation and generation of C3a and C5a via the different complement pathways.
    Wust SK; Blumenthal MN; Corazalla EO; Benson BA; Dalmasso AP
    Transl Res; 2006 Oct; 148(4):157-63. PubMed ID: 17002917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.
    Szebeni J; Muggia F; Gabizon A; Barenholz Y
    Adv Drug Deliv Rev; 2011 Sep; 63(12):1020-30. PubMed ID: 21787819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs.
    Szebeni J; Storm G
    Biochem Biophys Res Commun; 2015 Dec; 468(3):490-7. PubMed ID: 26182876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-mediated alternative complement pathway activation resists inhibition by sialoglycolipids.
    Okada N; Yasuda T; Okada H
    J Immunol; 1985 May; 134(5):3316-9. PubMed ID: 2580023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation.
    Szebeni J; Wassef NM; Spielberg H; Rudolph AS; Alving CR
    Biochem Biophys Res Commun; 1994 Nov; 205(1):255-63. PubMed ID: 7999033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement activation and thromboxane secretion by liposome-encapsulated hemoglobin in rats in vivo: inhibition by soluble complement receptor type 1.
    Szebeni J; Spielberg H; Cliff RO; Wassef NM; Rudolph AS; Alving CR
    Artif Cells Blood Substit Immobil Biotechnol; 1997 Jul; 25(4):347-55. PubMed ID: 9242930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction.
    Szebeni J; Baranyi L; Savay S; Bodo M; Morse DS; Basta M; Stahl GL; Bünger R; Alving CR
    Am J Physiol Heart Circ Physiol; 2000 Sep; 279(3):H1319-28. PubMed ID: 10993799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes.
    Chonn A; Cullis PR; Devine DV
    J Immunol; 1991 Jun; 146(12):4234-41. PubMed ID: 2040798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexplained intrauterine fetal death is accompanied by activation of complement.
    Richani K; Romero R; Soto E; Espinoza J; Nien JK; Chaiworapongsa T; Refuerzo J; Blackwell S; Edwin SS; Santolaya-Forgas J; Mazor M
    J Perinat Med; 2005; 33(4):296-305. PubMed ID: 16207114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles.
    Szebeni J; Alving CR; Rosivall L; Bünger R; Baranyi L; Bedöcs P; Tóth M; Barenholz Y
    J Liposome Res; 2007; 17(2):107-17. PubMed ID: 17613700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo applications of PEG liposomes: unexpected observations.
    Laverman P; Boerman OC; Oyen WJG ; Corstens FHM ; Storm G
    Crit Rev Ther Drug Carrier Syst; 2001; 18(6):551-66. PubMed ID: 11789675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.
    Szebeni J
    Toxicology; 2005 Dec; 216(2-3):106-21. PubMed ID: 16140450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses.
    Dézsi L; Fülöp T; Mészáros T; Szénási G; Urbanics R; Vázsonyi C; Őrfi E; Rosivall L; Nemes R; Kok RJ; Metselaar JM; Storm G; Szebeni J
    J Control Release; 2014 Dec; 195():2-10. PubMed ID: 25148822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of quercetin-loaded liposomes as potential drug carriers: in vitro evaluation of human complement activation.
    Landi-Librandi AP; Chrysostomo TN; Caleiro Seixas Azzolini AE; Marzocchi-Machado CM; de Oliveira CA; Lucisano-Valim YM
    J Liposome Res; 2012 Jun; 22(2):89-99. PubMed ID: 22011316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membrane sialoglycolipids regulate the activation of alternative complement pathway by liposomes containing trinitrophenylaminocaproyldipalmitoylphosphatidylethaolamine.
    Okada N; Yasuda T; Tsumita T; Okada H
    Immunology; 1983 Jan; 48(1):129-40. PubMed ID: 6848448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines.
    Szebeni J; Bedőcs P; Csukás D; Rosivall L; Bünger R; Urbanics R
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1706-16. PubMed ID: 22820530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.